Transcript Slide 1

Genomics Commercialization
Glen Schuler
Managing Director, Industry Liaison Office
University of Saskatchewan
Genomics Commercialization: Drug
Timeline
30%
The Canadian Biopharmaceutical Industry Technology Roadmap
R&D Drug Investment by
Function
Stage
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory Approval
Phase IV (Post Marketing)
Uncategorized
Percentage
25
7
7
11
23
12
11
4
Drug discovery = 25% of R&D costs and 45% of development time.
Tools such as genomics, bioinformatics, etc. have had minimal impact on R&D productivity when
measured by the number of drugs that have entered clinical trials and moved to regulatory approval.
Pharmaceutical Research and Manufacturers of
America, Annual Membership Survey, 2003
Genomics Commercialization
Genomics Commercialization
Glen Schuler
Managing Director, Industry Liaison Office
University of Saskatchewan